REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS Amgen (NASDAQ:AMGN) reported that Repatha (evolocumab) reduced first major adverse cardiovascular events by 31% in a high-risk primary prevention subgroup from VESALIUS-CV.The analysis (3,655 patients with diabetes, median 4.8 years) showed median LDL-C 44 mg/dL at 96 weeks versus 105 mg/dL for placebo; results were presented at ACC and published in JAMA.

#AMGN REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

www.stocktitan.net/news/AMGN/repatha-cuts-r...

Social post image

Big money is rotating into biotech and $AMGN is a prime beneficiary. AI-powered growth + analyst upgrades = hidden gem 💎

#amgn #neuwelt #stocks #growth #biotech

Social post image

Biotech rotation is heating up and $AMGN just hit all-time highs 🚀 Piper sees $432 target as AI meets healthcare growth

See the full breakdown on https://neuwelt.app/ticker/AMGN

#amgn #neuwelt #investing #stocks #biotech

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#AMGN, #OKE, #IBM, #INTU, #ADP

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #AMGN 94.3x
2. #OKE 17.6x
3. #IBM 13.4x
4. #INTU 12.3x
5. #KMX 12.1x

#OptionFlow #OptionsTrading #Trading

#AMGN #LLY #89b940f6-de78-432a-bfe4-41e4e6ffcb83 #investing #Health #Care

Origin | Interest | Match

Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access Sagebrush filed the lawsuit in the California Superior Court in Ventura County, where Amgen is headquartered. The complaint asserts five causes of action against Amgen for violating California law and seeks to protect patients’ access to affordable care, particularly for the economically challenged and uninsured populations Sagebrush primarily serves.

#AMGN Nonprofit Health Services Organization Files Lawsuit Against Fortune 500 Pharmaceutical Company Over Prescription Drug Access

www.stocktitan.net/news/AMGN/nonprofit-heal...

🤝 $AMGN to acquire Dark Blue Therapeutics for $840M | Adds DBT 3757, first-in-class MLLT1/3-targeted protein degrader for AML | Expands oncology pipeline

Dark Blue Therapeutics acquired by Amgen for up to $840 million Lead candidate in the MLLT1/3 programme, DBT 3757, is a differentiated investigational molecule designed to treat Acute Myeloid Leukemia Acquisition brings a new therapeutic mechanism to Amgen's extensive cancer portfolio– Dark Blue has pioneered the biology of targeting MLLT1/3, and DBT 3757 is designed to degrade MLLT 1/ 3 proteins in the Super...

#AMGN Dark Blue Therapeutics acquired by Amgen for up to $840 million

www.stocktitan.net/news/AMGN/dark-blue-ther...

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE Amgen (NASDAQ: AMGN) announced on Jan 6, 2026 the acquisition of Dark Blue Therapeutics for up to $840 million. The deal adds an investigational small molecule that targets and degrades proteins MLLT1/3, aimed at specific types of acute myeloid leukemia (AML).Preclinical leukemia models showed promising anti-cancer activity and a mechanism differentiated from current therapies, supporting potential single-agent and combination use to address treatment resistance and durability of remission. Amgen said it will integrate Dark Blue into its research organization to strengthen early oncology discovery and advance the program toward clinical investigation.

#AMGN AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE

www.stocktitan.net/news/AMGN/amgen-acquires...

AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS Underscores Long-Standing Commitment to Investing in Innovation and U.S. Manufacturing. THOUSAND OAKS, Calif., Dec. 19, 2025/ PRNewswire/-- Amgen today announced it is taking action again with the U.S. government to lower medicine costs for American patients, while reinforcing Amgen's long-standing commitment to innovation. "The U.S. leads the world in...

#AMGN AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS

www.stocktitan.net/news/AMGN/amgen-takes-ac...

22. The company that created BIO in biotechnology For our twenty-second episode, we’re heading into the laboratory. We're going to talk about a company that was one of the original pioneers of the biotechnology revolution. They don't make pills out of chemicals... no... they harness the power of living cells to create complex biologic drugs that can treat some of the most difficult diseases on Earth, from cancer to kidney failure to autoimmune disorders. We are talking about one of the founding fathers of biotech... Amgen. When you hear the name Amgen ($AMGN), you probably think of a pioneering biotech firm, one of the original giants of the industry. For decades, it has been a dominant force in medicine, developing blockbuster drugs for everything from arthritis to cancer and high cholesterol. Amgen is the undisputed king of mature biotechnology, a blue-chip stock in the Dow Jones Industrial Average known for its massive cash flows and shareholder returns. But in an industry defined by innovation, the biggest threat comes from within: patent expirations. With key drugs facing increasing competition from biosimilars, Amgen is in a race against time to refresh its portfolio. The company has responded with major acquisitions, like the nearly $28 billion purchase of Horizon Therapeutics, to bolster its pipeline of new drugs. Can Amgen’s aggressive M&A strategy and its own research and development successfully navigate the looming patent cliff, or is this defensive stalwart facing a period of slow growth? We're looking under the microscope to determine if Amgen's pipeline has the cure for its patent woes, making it a healthy addition to your portfolio.

📣 New Podcast! "22. The company that created BIO in biotechnology" on @Spreaker #amgen #amgn #analysis #biotech #bluechip #dividend #drugs #enbrel #finance #healthcare #horizon #investing #m_a #market #patent #pharma #pipeline #portfolio #stocks #valuation

🚨 Institutions #optionsvolume surge detected! PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #Z 30.7x
2. #AMGN 26.0x
3. #AGIO 23.3x
4. #ARWR 22.4x
5. #NOW 15.4x

#OptionFlow #OptionsTrading #Trading

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#Z, #AMGN, #ARWR, #NOW, #IAG

#OptionFlow #OptionsTrading #Trading

FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER Amgen (NASDAQ: AMGN) announced that the FDA granted full approval to IMDELLTRA (tarlatamab-dlle) on Nov 19, 2025 for adult patients with extensive stage small cell lung cancer (ES-SCLC) with progression after platinum-based chemotherapy. The decision converts prior accelerated approval based on the global Phase 3 DeLLphi-304 trial, which showed a 40% reduction in risk of death versus standard chemotherapy (median overall survival 13.6 vs. 8.3 months; HR 0.60; P < 0.001).The NCCN Guidelines were updated to list tarlatamab as the only Category 1 preferred option in this setting. Safety in DeLLphi-304 was consistent with known profile: fewer Grade ≥3 adverse events versus chemotherapy (54% vs. 80%); common IMDELLTRA toxicities included neutropenia (4%), lymphopenia (4%), and primarily low-grade cytokine release syndrome.

#AMGN FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER

www.stocktitan.net/news/AMGN/fda-grants-ful...

Tech Stocks Drop, Pharma Gains As Sector Rotation Picks Up: - Amgen (NASDAQ:AMGN) Wall Street endured another wave of selling in tech stocks on Tuesday, with the Nasdaq 100 down more than 1% by midday in New York, extending its month-to-date slide to more than 5%.

Tech Stocks Drop, Pharma Gains As Sector Rotation Picks Up: What's Moving Markets Tuesday? Wall Street endured another wave of selling in tech stocks on Tuesday, with the Nasdaq 100 down more t...

#$BTC #AMGN #AMZN #DECK #DIA #Equities #FCX #HD #IWM #Large #Cap

Origin | Interest | Match

#AMGN #GILD #4f46963d-308f-4b88-80dd-4b1306cf5e3a #investing #Health #Care

Origin | Interest | Match

JUST IN: ( NASDAQ: #AMGN ) AMGEN'S REPATHA CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL

AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL Amgen (NASDAQ:AMGN) reported Phase 3 VESALIUS-CV results showing Repatha (evolocumab) reduced first major adverse cardiovascular events by 25% (3‑P MACE) in >12,000 high‑risk adults without prior heart attack or stroke when added to LDL‑lowering therapy.The trial also showed a 36% reduction in heart attack, a 19% reduction in 4‑P MACE, and median achieved LDL‑C of 45 mg/dL versus 109 mg/dL for placebo. No new safety signals were identified. Results presented at AHA 2025 and published in NEJM.

#AMGN AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL

www.stocktitan.net/news/AMGN/amgen-s-repath...

after earnings:

#AMGN Amgen = +2%
#RIVN Rivian = +3%
#MARA Marathon Digital = -1%
#SMCI SuperMicro = -10%
#AMD AMD = -5%
#PINS Pinterest = -20%

AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS THOUSAND OAKS, Calif., Nov. 4, 2025/ PRNewswire/-- Amgen today announced financial results for the third quarter of 2025.. For the third quarter, total revenues increased 12% to $9.6 billion in comparison to the third quarter of 2024. Product sales grew 12%, driven by 14% volume growth, partially offset by 4% lower net selling price. Sixteen products delivered at least...

#AMGN AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

www.stocktitan.net/news/AMGN/amgen-reports-...

This week we're tracking 750+ companies releasing their quarterly reports. Check our #Earnings calendar, add #estimates and compete with industry analysts: 📊➡️ tinyurl.com/ys7j253d #AMD, #AMGN, #APP, #DDOG, #FTNT, #HIMS, #HOOD, #MCD, #MNST, #NVO, #PFE, #PLTR, #QCOM, #SHOP, #SMCI, #TTD, #UBER, #XYZ

AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025 Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events in High-Risk Patients Who Have Never Had a Heart Attack or Stroke. Real-World Evidence from the Repatha-CE Trial Reinforces Its Position as a Leading LDL-C Lowering Therapy for Reducing Cardiovascular Events. THOUSAND OAKS, Calif., Oct. 31, 2025/ PRNewswire/-- Amgen...

#AMGN AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025

www.stocktitan.net/news/AMGN/amgen-s-landma...

PSL reveals W15 Westernleague S5 Results! stock of the week Intuitive Surgical

#TSLA def #AAPL by 0.419 pts
#ISRG def #T by 26.639 pts
#UBER def #AMGN by 3.524 pts
#XOM def #WMT by 4.54 pts
#INTU def #WM by 3.679 pts
#DIS def #AMD by 2.617 pts
#PANW def #SCHW
#NOW def #AVGO

#stockmarket #investing

FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS Amgen (NASDAQ:AMGN) and AstraZeneca announced FDA approval on October 17, 2025 of TEZSPIRE (tezepelumab-ekko) for add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in patients aged 12 years and older. TEZSPIRE is the first biologic for CRSwNP that targets thymic stromal lymphopoietin (TSLP). Approval was supported by the WAYPOINT Phase III trial, which showed a statistically significant reduction in nasal polyp severity, near-elimination of the need for surgery, and significant reduction in systemic corticosteroid use versus placebo. Safety was described as generally consistent with the drug's established severe asthma profile. Regulatory applications are under review in Europe, China, Japan and other countries.

#AMGN FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS

www.stocktitan.net/news/AMGN/fda-approves-t...

PSL reveals W14 Westernleague S5 Results! stock of the week: Walmart

#TSLA def #ISRG by 0.599 pts
#AMGN def #AAPL by 2.891 pts
#T def #XOM by 2.373 pts
#INTU def #UBER by 4.083 pts
#WMT def #AMD by 3.654 pts
#WM def #PANW by 2.661 pts
#AVGO def #DIS b
#SCHW def #NOW

#stockmarket #investing #stocks

PSL reveals W13 Westernleague S5 Results! stock of the week: AMD

#TSLA def #AMGN by 0.546 pts
#XOM def #ISRG by 1.305 pts
#AAPL def #INTU by 4.164 pts
#AMD def #T by 21.363 pts
#PANW def #UBER by 3.448 pts
#AVGO def #WMT by 1.967 pts
#NOW def #WM by 0.664 pts
#SCHW def #DIS

#stockmarket #investing

AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S. Amgen (NASDAQ: AMGN) launched AmgenNow, a U.S. direct-to-patient program making Repatha (evolocumab) available at a monthly price of $239, nearly 60% below the current U.S. list price, starting Oct 6, 2025. The offer is open to all patients, including uninsured, high-deductible plan holders, cash payers, and participants in Medicare and Medicaid.Amgen said Repatha has helped over 5 million patients and cited VESALIUS-CV Phase 3 results showing reduced major adverse cardiovascular events; patients using AmgenNow will not face insurer step therapy or prior authorization. Amgen described $239 as the lowest Repatha price among G-7 countries and plans TrumpRx availability.

#AMGN AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.

www.stocktitan.net/news/AMGN/amgen-makes-re...

#AMGN #330853df-102d-471e-8a6d-f76c3b1b2fe4 #investing

Origin | Interest | Match

PSL reveals W12 Westernleague S5 Results! stock of the week: Amgen

#TSLA def #XOM by 6.482 pts
#AMGN def #INTU by 10.367 pts
#AMD def #ISRG by 4.437 pts
#PANW def #AAPL by 3.751 pts
#AVGO def #T by 5.311 pts
#NOW def #UBER by 0.018 pts
#WMT def #SCHW by 0.663 pts
#WM def #DIS by 0.60

#stockmarket